Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mesa

Showing results (11-20 of 472) with videos related to

Pageof 48
Sort By:
Current Hematology Reports|August 7, 2003
Myelofibrosis with myeloid metaplasia: therapeutic options in 2003Ruben A Mesa
Expert Review of Anticancer Therapy|March 1, 2006
Tipifarnib: farnesyl transferase inhibition at a crossroadsRuben A Mesa
Oncology (Williston Park, N.Y.)|August 28, 2013
Improving disease burden in myelofibrosis: changing the natural history of the diseaseRuben A Mesa
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
Recent advances in the management of myelofibrosisRuben A Mesa
Clinical Advances in Hematology & Oncology : H&O|September 25, 2019
Proactive steps to optimize the management of polycythemia vera and myelofibrosisRuben A Mesa
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2017
NCCN Debuts New Guidelines for Myeloproliferative NeoplasmsRuben A Mesa
Hematology. American Society of Hematology. Education Program|January 18, 2011
Assessing new therapies and their overall impact in myelofibrosisRuben A Mesa
Leukemia Research|February 9, 2010
Detangling fibrosis assessment in MPNsRuben A Mesa
American Health & Drug Benefits|November 17, 2015
Letter to Our ReadersRuben A Mesa
Idrugs : the Investigational Drugs Journal|May 28, 2010
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasisRuben A Mesa
Pageof 48

Showing results (11-20 of 472) with videos related to

Sort By:
Pageof 48
Current Hematology Reports|August 7, 2003
Myelofibrosis with myeloid metaplasia: therapeutic options in 2003Ruben A Mesa
Expert Review of Anticancer Therapy|March 1, 2006
Tipifarnib: farnesyl transferase inhibition at a crossroadsRuben A Mesa
Oncology (Williston Park, N.Y.)|August 28, 2013
Improving disease burden in myelofibrosis: changing the natural history of the diseaseRuben A Mesa
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
Recent advances in the management of myelofibrosisRuben A Mesa
Clinical Advances in Hematology & Oncology : H&O|September 25, 2019
Proactive steps to optimize the management of polycythemia vera and myelofibrosisRuben A Mesa
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2017
NCCN Debuts New Guidelines for Myeloproliferative NeoplasmsRuben A Mesa
Hematology. American Society of Hematology. Education Program|January 18, 2011
Assessing new therapies and their overall impact in myelofibrosisRuben A Mesa
Leukemia Research|February 9, 2010
Detangling fibrosis assessment in MPNsRuben A Mesa
American Health & Drug Benefits|November 17, 2015
Letter to Our ReadersRuben A Mesa
Idrugs : the Investigational Drugs Journal|May 28, 2010
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasisRuben A Mesa
Pageof 48